CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Other Events

CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

On February 1, 2018, Corvus Pharmaceuticals, Inc. issued a press release announcing data from its preclinical study of its novel T-cell signaling pathway inhibitor, in connection with the presentation of such data at the 10th Annual T-Cell Lymphoma Forum. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

99.1

Press release titled, “Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum” dated February 1, 2018.


Corvus Pharmaceuticals, Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma ForumCompany’s Investigational Small Molecule Inhibitor Demonstrates Safety and Activity in Canine Spontaneous T-Cell Lymphoma BURLINGAME,…
To view the full exhibit click here

About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

An ad to help with our costs